Novel self-associating poly(ethylene oxide)-b-poly(ε-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery

International Journal of Pharmaceutics

Volumn 389, Issue 1-2, 2010, Pages 213-222

  Shahin, Mostafa ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Paclitaxel; Poly(ethylene oxide) block poly( caprolactone); Polymer drug conjugate; Polymeric micelles

Indexed keywords

PACLITAXEL; POLY(ETHYLENE OXIDE) BETA POLY(EPSILON CAPROLACTONE); POLYMER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PURIFICATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; INCUBATION TIME; PARTICLE SIZE; PH; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; VISCOSITY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; LACTONES; MICELLES; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SOLUBILITY; TIME FACTORS;

EID: 77349111010     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.01.015     Document Type: Article

References (39)

1. Boyle D.A., and Goldspiel B.R. A review of paclitaxel (Taxol) administration, stability, and compatibility issues. Clin. J. Oncol. Nurs. 2 (1998) 141-145
2. Chen Q., Zhang Q.Z., Liu J., Li L.Q., Zhao W.H., Wang Y.J., Zhou Q.H., and Li L. Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-small-cell lung cancer. Chin. J. Oncol. 25 (2003) 190-192
3. Cho Y., Lee J., Lee S., Huh K., and Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J. Control. Release 97 (2004) 249-257
4. Costa P., and Sousa Lobo J.M. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13 (2001) 123-133
5. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
6. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
7. Edelman M.J. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin. Lung Cancer 10 (2009) S30-34
8. Forrest M.L., Yanez J.A., Remsberg C.M., Ohgami Y., Kwon G.S., and Davies N.M. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm. Res. 25 (2008) 194-206
9. Goldspiel B.R. Clinical overview of the taxanes. Pharmacotherapy 17 (1997) 110S-125S
10. Greenwald R.B., Pendri A., Bolikal D., and Gilbert C.W. Highly water soluble taxol derivatives: 2′-polyethyleneglycol esters as potential prodrugs. Bioorg. Med. Chem. Lett. 4 (1994) 2465-2470
11. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39 (1996) 424-431
12. Gregory R.E., and DeLisa A.F. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin. Pharm. 12 (1993) 401-415
13. Hans M., Shimoni K., Danino D., Siegel S.J., and Lowman A. Synthesis and characterization of mPEG-PLA prodrug micelles. Biomacromolecules 6 (2005) 2708-2717
14. Hu F.-Q., Ren G.-F., Yuan H., Du Y.-Z., and Zeng S. Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf. B: Biointerfaces 50 (2006) 97-103
15. Langer C.J. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin. Lung Cancer 6 (2004) S85-88
16. Lavasanifar A., Samuel J., and Kwon G.S. The effect of alkyl core structure on micellar properties of poly(ethylene oxide)-block-poly(l-aspartamide) derivatives. Colloids Surf. B: Biointerfaces 22 (2001) 115-126
17. Letchford K., Liggins R., and Burt H. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J. Pharm. Sci. 97 (2008) 1179-1190
18. Letchford K., Liggins R., Wasan K., and Burt H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur. J. Pharm. Biopharm. 71 (2009) 196-206
19. Li Y., and Kwon G.S. Micelle-like structures of poly (ethylene oxide)-block-poly (2-hydroxyethyl aspartamide)-methotrexate conjugates. Colloids Surf. B: Biointerfaces 16 (1999) 217-226
20. Mahmud A., Xiong X.B., and Lavasanifar A. Novel self-associating poly(ethylene oxide)-block-poly ([epsilon]-caprolactone) block copolymers with functional side groups on the polyester block for drug delivery. Macromolecules 39 (2006) 9419-9428
21. Mahmud A., Xiong X.B., and Lavasanifar A. Development of novel polymeric micellar drug conjugates and nano-containers with hydrolyzable core structure for doxorubicin delivery. Eur. J. Pharm. Biopharm. 69 (2008) 923-934
22. Mahmud A., Patel S., Molavi O., Choi P., Samuel J., and Lavasanifar A. Self-associating poly(ethylene oxide)-b-poly(alpha-cholesteryl carboxylate-epsilon-caprolactone) block copolymer for the solubilization of STAT-3 inhibitor cucurbitacin I. Biomacromolecules (2009)
23. Mazzo D.J., Nguyen-Huu J.J., Pagniez S., and Denis P. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am. J. Health Syst. Pharm. 54 (1997) 566-569
24. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H., Schot M., Mandjes I.A., Zurlo M.G., Rocchetti M., Rosing H., Koopman F.J., and Beijnen J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12 (2001) 315-323
25. Onetto N., Canetta R., Winograd B., Catane R., Dougan M., Grechko J., Burroughs J., and Rozencweig M. Overview of Taxol safety. J. Natl. Cancer Inst. Monogr. (1993) 131-139
26. Pendri A., Conover C.D., and Greenwald R.B. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anticancer Drug Des. 13 (1998) 387-395
27. Ringel I., and Horwitz S.B. Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J. Pharmacol. Exp. Ther. 242 (1987) 692-698
28. Sharma U.S., Balasubramanian S.V., and Straubinger R.M. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci. 84 (1995) 1223-1230
29. Singer J.W. Paclitaxel poliglumex (XYOTAXCT-2103): a macromolecular taxane. J. Control. Release 109 (2005) 120-126
30. Singer J.W., Baker B., De Vries P., Kumar A., Shaffer S., Vawter E., Bolton M., and Garzone P. Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 519 (2003) 81-99
31. Singer J.W., Shaffer S., Baker B., Bernareggi A., Stromatt S., Nienstedt D., and Besman M. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 16 (2005) 243-254
32. Singla A., Garg A., and Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235 (2002) 179-192
33. Skwarczynski M., Hayashi Y., and Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem. 49 (2006) 7253-7269
34. Sparreboom A., van Zuylen L., Brouwer E., Loos W., de Bruijn P., Gelderblom H., Pillay M., Nooter K., Stoter G., and Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59 (1999) 1454-1457
35. Vaisman B., Shikanov A., and Domb A.J. Normal phase high performance liquid chromatography for determination of paclitaxel incorporated in a lipophilic polymer matrix. J. Chromatogr. A 1064 (2005) 85-95
36. Wall M.E., and Wani M.C. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 55 (1995) 753-760
37. Yao J.H., Mya K.Y., Li X., Parameswaran M., Xu Q.-H., Loh K.P., and Chen Z.-K. Light scattering and luminescence studies on self-aggregation behavior of amphiphilic copolymer micelles. J. Phys. Chem. B 112 (2008) 749-755
38. Yokoyama M., Fukushima S., Uehara R., Okamoto K., Kataoka K., Sakurai Y., and Okano T. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J. Control. Release 50 (1998) 79-92
39. Zhao C.L., Winnik M.A., Riess G., and Croucher M.D. Fluorescence probe techniques used to study micelle formation in water-soluble block copolymers. Langmuir 6 (1990) 514-516